The Globe and Mail

Go to the Globe and Mail homepage

Jump to main navigationJump to main content

The Globe and Mail has
updated our Stock Quote Pages
You are about to experience the newly designed Stock Quote Pages format. With the new layout, you'll enjoy a more in-depth look at the companies you're following and pages that are easier to navigate. This Editors' blog post explains why we've made these changes.

 

GlaxoSmithKline PLC

NYSE: GSK
Last

(U.S.) $43.59

Today's change0.00 0.00%
Updated July 30 4:01 PM EDT. Delayed by at least 15 minutes.
 

GlaxoSmithKline PLC

NYSE: GSK
Last

(U.S.) $43.59

Today's change0.00 0.00%
Updated July 30 4:01 PM EDT. Delayed by at least 15 minutes.

GlaxoSmithKline PLC closed at (U.S.)$43.59.

Over the last five days, shares have gained 3.79%, but are currently unchanged over the last year to date. Shares have underperformed the S&P 500 by 17.10% during the last year.

Key company metrics

  • Open(U.S.) $0.00
  • Previous close(U.S.) $43.59
  • High--
  • Low--
  • Bid / Ask(U.S.) $43.36 / (U.S.) $43.40
  • YTD % change+1.99%
  • Volume8,220
  • Average volume (10-day)4,228,699
  • Average volume (1-month)4,236,137
  • Average volume (3-month)4,111,967
  • 52-week range(U.S.) $41.19 to (U.S.) $49.24
  • Beta0.66
  • Trailing P/E6.62×
  • P/E 1 year forward18.63×
  • Forward PEG2.45×
  • Indicated annual dividend(U.S.) $2.53
  • Dividend yield5.81%
  • Trailing EPS(U.S.) $6.58
Updated July 30 4:01 PM EDT. Delayed by at least 15 minutes.

Profit

Net Profit (TTM)
+40.97%

Based on its net profit margin of 40.97%, GlaxoSmithKline PLC is among the more effective companies in its industry at turning revenues into bottom line profit.
Company Books

S&P TSX0.00%Sector:Industry:
  • Income Statement
  • Balance Sheet
  • Cash Flow
Quarter | Annual
Q1/2015Q4/2014Q3/2014Q2/2014
Fiscal Quarter Endvalues in $ millions unless otherwise notedMar 31, 201503/31/2015Dec 31, 201412/31/2014Sep 30, 201409/30/2014Jun 30, 201406/30/2014
Revenue5,6226,1865,6465,561
Total other revenue--------
Total revenue5,6226,1865,6465,561
Gross profit3,7454,2783,8943,888
Total cost of revenue1,8771,9081,7521,673
Total operating expense-4,4375,4954,9434,424
Selling / general / administrative1,9511,9391,7951,969
Research & development789821742766
Depreciation / amortization13151717
Interest expense (income), net operating--------
Unusual expense (income)-8,99053273871
Other operating expenses, total-77280-101-72
Operating income10,0596917031,137
Interest income (expense), net non-operating--------
Gain (loss) on sale of assets--------
Other--------
Income before tax9,923531548986
Income after tax8,0381,025385702
Income tax, total1,885-494163284
Net income8,0891,033401654
Total adjustments to net income--------
Net income before extra. items8,0891,033401654
Minority interest51816-48
Equity in affiliates--------
U.S. GAAP adjustment--------
Inc. avail. to common excl. extra. items8,0891,033401654
Inc. avail. to common incl. extra. items8,0891,033401654
Diluted net income8,0891,033401654
Dilution adjustment--------
Diluted weighted average shares4,8204,8114,8654,874
Diluted EPS excluding extraordinary itemsvalue per share1.680.210.080.13
Dividends per sharevalue per share0.190.230.190.19
Diluted normalized EPSvalue per share0.170.190.210.16